The Voltage-Gated Calcium Channel Collective (VGCCC) is a global, multi-stakeholder initiative accelerating scientific understanding, clinical development and care for individuals affected by rare voltage-gated calcium channel (VGCC) disorders.

These conditions—often severe, multisystem and underdiagnosed—span a spectrum of neurological, cardiac and neurodevelopmental challenges. While individually rare, they share biological mechanisms, clinical overlap and opportunities for cross-gene therapeutic strategies.

The VGCCC connects patient-led organisations, clinicians, researchers and industry partners across gene-specific communities to:

Promote awareness of calcium channelopathies in clinical and research settings

Facilitate cross-gene learning to inform diagnosis, care standards and treatment development

Provide lived-experience insights that enhance trial design, outcome measures and patient engagement

Encourage strategic collaboration to unlock scalable, cross-cutting solutions in precision medicine

Current genes represented include:
CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S

The VGCCC offers a unique platform for drug developers and translational researchers seeking deeper access to patient communities, real-world insights and partnerships that accelerate meaningful innovation in rare ion channel disorders.

To learn more or explore collaboration, visit thevgccc.org.

The VGCCC

Org chart

Teams

Offices